Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Epstein-Barr Virus: Inhibition of Replication by Three New Drugs

Jung-Chung Lin, M. Carolyn Smith, Yung-Chi Cheng and Joseph S. Pagano
Science
New Series, Vol. 221, No. 4610 (Aug. 5, 1983), pp. 578-579
Stable URL: http://www.jstor.org/stable/1691242
Page Count: 2
  • More info
  • Cite this Item
Preview not available
Preview not available

Abstract

Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and is associated with three human malignancies. Acyclovir [9-(2-hydroxyethoxymethyl)guanine], the first clinically useful drug effective against replication of EBV, is without effect against latent or persistent EBV infection. Three nucleoside analogs, E-5-(2-bromovinyl)-2′-deoxyuridine, 1-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)-5-iodocytosine, and 1-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)-5-methyluracil are potent inhibitors of EBV replication in vitro. Moreover, in contrast to the reversibility of viral inhibition by Acyclovir, these three drugs have prolonged effects in suppressing viral replication even after the drugs are removed from persistently infected cell cultures.

Page Thumbnails

  • Thumbnail: Page 
578
    578
  • Thumbnail: Page 
579
    579